期刊文献+

双预激方案治疗难治复发性急性髓系白血病的疗效观察 被引量:2

Effect of double pre treatment on refractory and relapsed acute myeloid leukemia
下载PDF
导出
摘要 目的评价双预激(CHAG)方案对难治复发性急性髓系白血病(ANLL)且不能耐受大剂量化疗患者的疗效、耐受性及不良反应。方法予粒细胞集落刺激因子[G-CSF 100~200μg/(m^2·d),第1天~第14天,皮下注射]、阿克拉霉素(Acla 8~10mg/d,第1天~第8天,静脉输注)、高三尖杉酯碱[1mg/(m^2·d),第1天~第14天,静脉输注]、小剂量阿糖胞苷[Ara-C,8~10mg/(m^2·d),第1天~第14天,每12小时皮下注射]在内的CHAG方案治疗难治、复发性ANLL 9例。结果5例(55.5%)患者取得完全缓解(CR),2例(22.2%)获部分缓解(PR),总有效率77.7%。化疗期间出现骨髓抑制、继发感染及发热等不良反应,无严重不良反应。结论双预激方案治疗难治复发性ANLL疗效较好,毒副反应轻,值得临床推广。 Objectives To evaluate the double pre-excitation syndrome( CHAG) scheme for refractory recurrent acute myeloid leukemia( ANLL) and cannot tolerate high doses of chemotherapy in patients with efficacy, tolerability and adverse reactions. Methods Granulocyte colony stimulating factor [g-csf 100 ~ 200μg /( m^2·d),day 1 ~ 14 days,subcutaneous injection],Accra toxin( Acla 8 ~ 10 mg / d,day 1 ~ 8days,intravenous),three pointed cedar ester alkali( 1mg /( m^2·d),day 1 ~ 14 days,intravenous),to low-dose cytarabine [Ara-C,8 ~ 10 mg /( m^2·d),day 1 ~ 14 days,every 12 hours subcutaneous injection],CHAG scheme in the treatment of refractory,9 cases of recurrent ANLL. Results 5 cases( 55. 5%) patients achieved complete remission( CR),2 cases( 22. 2%) received partial response( PR),the total effective rate was 77. 7%. Shown during chemotherapy adverse reactions such as bone marrow suppression,secondary infection and fever,no serious adverse reactions. Conclusions Double preexcitation syndrome patients with refractory recurrent ANLL curative effect is good,adverse reaction,worth clinical promotion.
出处 《中国老年保健医学》 2015年第6期103-105,共3页 Chinese Journal of Geriatric Care
关键词 双预激方案难治 复发性急性髓系白血病 Double pre-excitation syndrome Refractory and recurrent Acute myeloid leukemia
  • 相关文献

参考文献7

二级参考文献15

  • 1吴德沛,傅琤琤,唐晓文,孙爱宁,马骁,苗瞄,刘跃,均张日,夏学鸣.含有大剂量阿糖胞苷的联合化疗治疗难治和复发急性白血病[J].中华血液学杂志,2004,25(11):696-697. 被引量:32
  • 2刘艳艳,张莉,魏旭东,汪萍,宋永平.预激疗法治疗难治性急性髓细胞白血病疗效分析[J].临床血液学杂志,2005,18(1):19-21. 被引量:16
  • 3刘海川,卞寿庚.急性白血病的治疗[J].中国实用内科杂志,1994,14(9):515-543. 被引量:18
  • 4秘营昌,薛艳萍,俞文娟,刘世和,赵耀中,孟庆祥,卞寿庚,王建祥.HA为基础的三药方案治疗急性髓系白血病疗效分析及与染色体核型的关系[J].中华血液学杂志,2005,26(12):705-709. 被引量:19
  • 5Yamada K,Furusawa S,Saito K,et al.Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia:a pilot study.Leukemia,1995,9:10-14.
  • 6Bai A,Kojima H,Hori M,et al.Priming with G-CSF effectively enhances low-dose Ara-C-induced in vivo apoptosis in myeloid leukemia cells.Exp Hematol,1999,27:259-265.
  • 7Katagiri T,Miyazawa K,Nishimaki J,et al.Combination of granulocyte colony-stimulating factor and low-dose cytosine arabinoside further enhances myeloid differentiation in leukemia cells in vitro.Leuk Lymphoma,2000,39:173-184.
  • 8Spadea A,Petti MC,Fazi P,et a1.Mitoxantrone.etoposide and intermediate-dose ara—C:an effective regimen for poor risk acute myeloid leukemia.Lekemia,1993,7:549—552.
  • 9Davis C L,Rohatiner A Z S,Lim J,et a1.The management of recurrent acute myelogenous leukaemia at a single center over a 15-year period.Br J Haematol,1993,83:404—411.
  • 10Lowenberg B,Touw I P.Hematopoietic growth factors and their receptors in acute leukemia.Blood,1993,81:281—292.

共引文献45

同被引文献16

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部